Form 4: KalVista CEO Sells Shares for Tax Obligations
Insider Transaction Report
KalVista Pharmaceuticals CEO Benjamin Palleiko sold shares to cover tax obligations following the vesting of restricted stock units.
Summary
- Benjamin L. Palleiko, CEO and Director of KalVista Pharmaceuticals, Inc. (KALV), acquired 9,362 shares of common stock on August 17, 2025, through the exercise of restricted stock units (RSUs) and performance stock units (PSUs).
- Following the acquisition, Palleiko beneficially owned 378,957 shares of common stock.
- On August 18, 2025, Palleiko sold 4,409 shares of common stock at a price of $13.187 per share.
- The sale was explicitly stated as a 'sell to cover' transaction to satisfy tax withholding obligations related to the vesting and settlement of RSUs and PSUs, and was not a discretionary transaction.
- After the sale, Palleiko's direct beneficial ownership of common stock was 374,548 shares.
- Two tranches of RSUs were exercised: 2,418 units (vesting 1/16th quarterly from August 17, 2022) and 6,944 units (vesting 1/12th quarterly from November 17, 2022).
Sentiment
Score: 5
Explanation: The sentiment is neutral. The transaction is a non-discretionary 'sell to cover' to satisfy tax obligations from RSU/PSU vesting, which is a standard event and does not indicate positive or negative sentiment towards the company's prospects.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This filing is a routine insider transaction (Form 4) related to executive compensation and tax obligations, and does not provide broader industry context or trends for the pharmaceutical sector.
Stakeholder Impact
- Shareholders: The sale of shares by the CEO is a routine 'sell to cover' transaction for tax purposes and is unlikely to have a significant impact on shareholder perception or the company's stock price, as it is not a discretionary sale.
Key Dates
| Date | Description |
|---|---|
| 08/17/2022 | Vesting commencement date for a tranche of Restricted Stock Units (RSUs) vesting 1/16th quarterly. |
| 11/17/2022 | Vesting commencement date for a tranche of Restricted Stock Units (RSUs) vesting 1/12th quarterly. |
| 08/17/2025 | Date of acquisition of 9,362 common shares through exercise of derivative securities (RSUs/PSUs). |
| 08/18/2025 | Date of sale of 4,409 common shares to cover tax withholding obligations. |
| 08/19/2025 | Date the Form 4 was signed and filed. |
Keywords
KalVista Pharmaceuticals, KALV, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Performance Stock Units, CEO, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.